652-62-0 Usage
Description
4,6-Pyrimidinediol, 1,2-dihydro-5-nitro-2-(trifluoromethyl)-, also known as 2-(trifluoromethyl)-5-nitro-1,2-dihydropyrimidine-4,6-diol, is a chemical compound with the molecular formula C5H4N4O4CF3. It is a nitro-substituted derivative of 4,6-pyrimidinediol. 4,6-Pyrimidinediol, 1,2-dihydro-5-nitro-2-(trifluoromethyl)is of interest in the field of medicinal chemistry due to its potential biological activity. Its unique structure and properties make it a promising candidate for various applications in drug synthesis and development.
Uses
Used in Pharmaceutical Industry:
4,6-Pyrimidinediol, 1,2-dihydro-5-nitro-2-(trifluoromethyl)is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and potential biological activity make it a valuable building block for the development of new drugs with improved therapeutic properties.
Used in Medicinal Chemistry Research:
4,6-Pyrimidinediol, 1,2-dihydro-5-nitro-2-(trifluoromethyl)is used as a research tool in medicinal chemistry to explore its potential biological activity and evaluate its efficacy in treating various diseases. Its unique structure allows researchers to investigate its interactions with biological targets and understand its mechanism of action.
Used in Drug Design and Optimization:
4,6-Pyrimidinediol, 1,2-dihydro-5-nitro-2-(trifluoromethyl)is used in drug design and optimization processes to improve the potency, selectivity, and pharmacokinetic properties of drug candidates. Its unique structural features can be exploited to design drugs with enhanced therapeutic effects and reduced side effects.
Used in Drug Discovery:
4,6-Pyrimidinediol, 1,2-dihydro-5-nitro-2-(trifluoromethyl)serves as a starting point for drug discovery efforts, as its potential biological activity and unique structure can be leveraged to identify novel therapeutic agents. Researchers can use this compound as a template to develop new drugs with improved efficacy and safety profiles.
Check Digit Verification of cas no
The CAS Registry Mumber 652-62-0 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 6,5 and 2 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 652-62:
(5*6)+(4*5)+(3*2)+(2*6)+(1*2)=70
70 % 10 = 0
So 652-62-0 is a valid CAS Registry Number.
InChI:InChI=1/C5H2F3N3O4/c6-5(7,8)4-9-2(12)1(11(14)15)3(13)10-4/h(H2,9,10,12,13)
652-62-0Relevant articles and documents
Discovery of triazolopyrimidine-based PDE8B inhibitors: Exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes
Deninno, Michael P.,Wright, Stephen W.,Etienne, John B.,Olson, Thanh V.,Rocke, Benjamin N.,Corbett, Jeffrey W.,Kung, Daniel W.,Dirico, Kenneth J.,Andrews, Kim M.,Millham, Michele L.,Parker, Janice C.,Esler, William,Van Volkenburg, Maria,Boyer, David D.,Houseknecht, Karen L.,Doran, Shawn D.
scheme or table, p. 5721 - 5726 (2012/09/22)
PDE8B is a cAMP-specific isoform of the broader class of phosphodiesterases (PDEs). As no selective PDE8B inhibitors had been reported, a high throughput screen was run with the goal of identifying selective tools for exploring the potential therapeutic utility of PDE8B inhibition. Of the numerous hits, one was particularly attractive since it was amenable to rapid deconstruction leading to inhibitors with very high ligand efficiency (LE) and lipophilic ligand efficiency (LLE). These triazolopyrimidines were optimized for potency, selectivity and ADME properties ultimately leading to compound 42. This compound was highly potent and selective with good bioavailability and advanced into pre-clinical development.
PYRIMIDINE DERIVATIVES FOR THE TREATMENT OP GABA B MEDIATED NERVOUS SYSTEM DISORDERS
-
Page/Page column 26-27, (2010/11/25)
The invention relates to novel heterocyclic compounds of the formula (I) in free base form or in acid addition salt form, in which R1, R2, R3, R4 and A are as defined in the specification, to their preparation, to their use as medicaments for the treatment of certain nervous system disorders and to medicaments comprising them.
